Hemostasis in patients with normal and impaired renal function under treatment with cefodizime

Ten patients (two with normal, eight with impaired renal function) on their usual diet were treated with cefodizime (HR 221) for seven days. The dosage was 4 g/day, adapted to renal function as appropriate. Platelet function, plasma coagulation and vitamin K metabolism were investigated before and o...

Full description

Saved in:
Bibliographic Details
Published in:Infection 1987-09, Vol.15 (5), p.348-350
Main Authors: ANDRASSY, K, KODERISCH, J, TRENK, D, JÄHNCHEN, E, IWAND, A
Format: Article
Language:English
Subjects:
Adult
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - drug therapy
Biological and medical sciences
Bleeding Time
Blood Coagulation - drug effects
Cefotaxime - analogs & derivatives
Cefotaxime - pharmacology
Cefotaxime - therapeutic use
Chemical Phenomena
Chemistry
Female
Hemostasis - drug effects
Humans
Kidney Diseases - blood
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Platelet Aggregation - drug effects
Platelet Count - drug effects
Vitamin K - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ten patients (two with normal, eight with impaired renal function) on their usual diet were treated with cefodizime (HR 221) for seven days. The dosage was 4 g/day, adapted to renal function as appropriate. Platelet function, plasma coagulation and vitamin K metabolism were investigated before and on day 7 of therapy. Platelet function and plasma coagulation remained unchanged, regardless of the size of the serum antibiotic trough levels, in both normal and impaired renal function. Vitamin K1 metabolism remained unaffected, since no increase in vitamin K1 2,3 epoxide in the circulation was observed during the therapy. Cefodizime (HR 221), a parenteral aminothiazole cephalosporin, does not affect hemostasis.
ISSN:0300-8126
1439-0973
DOI:10.1007/BF01647736